ImmunoGen, Inc. To Present at the Cowen and Company 27th Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 6, 2007--ImmunoGen, Inc. (Nasdaq: IMGN) is scheduled to present at the Cowen and Company 27th Annual Health Care Conference at 11:00 am ET on March 13, 2007. The presentation will be webcast live and can be accessed through the "Investor Relations" section of the ImmunoGen website, www.immunogen.com. An archive of the webcast will be available at the same location until March 20, 2007.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing - huN901-DM1 and huC242-DM4. Companies licensing the right to develop anticancer compounds to specific targets using ImmunoGen's TAP technology include Biogen Idec, Biotest AG, Centocor (Johnson & Johnson), Genentech, and sanofi-aventis. Three anticancer compounds are in clinical testing through ImmunoGen's collaborations with other companies - AVE9633 and AVE1642, in development by sanofi-aventis, and trastuzumab-MCC-DM1, in development by Genentech.
CONTACT:
Investors
ImmunoGen, Inc.
Carol Hausner, 617-995-2500
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
